ZINBRYTA (daclizumab), immunosuppressant

NEUROLOGY - New medicinal product

Opinions on drugs - Posted on Mar 13 2017

Inclusion

ZINBRYTA, administered subcutaneously, has Marketing Authorisation in relapsing forms of multiple sclerosis (MS) in adults. This indication includes relapsing/remitting (RR) MS, relapsing secondary progressive (SP) MS and patients who presented a single demyelinising event.
It is a therapeutic alternative usable in first or second-line treatment in all relapsing forms of MS.
Its superiority has been demonstrated relative to a first-line treatment (interferon β1a AVONEX) in terms of annualised relapse rates to the detriment of a less-favourable safety profile, particularly with serious adverse events.
The absence of direct comparison with treatments indicated in highly active forms of RRMS does not allow its contribution in these patients to be quantified.
However, there are no data documenting its efficacy or safety in patients with relapsing SPMS.

Substantial

no clinical added value

Therapeutic use

Évaluation des médicaments

All our publications

My account